PL185320B1 - Kompozycja farmaceutyczna do stosowania miejscowego, zawierająca askomycynę - Google Patents

Kompozycja farmaceutyczna do stosowania miejscowego, zawierająca askomycynę

Info

Publication number
PL185320B1
PL185320B1 PL95347120A PL34712095A PL185320B1 PL 185320 B1 PL185320 B1 PL 185320B1 PL 95347120 A PL95347120 A PL 95347120A PL 34712095 A PL34712095 A PL 34712095A PL 185320 B1 PL185320 B1 PL 185320B1
Authority
PL
Poland
Prior art keywords
ascomycin
water
emulsion
composition
oil
Prior art date
Application number
PL95347120A
Other languages
English (en)
Polish (pl)
Inventor
Martin Jackman
Xue-Ping Popp
Friedrich Richter
Frittz Schmook
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/EP1995/004208 external-priority patent/WO1996013249A1/en
Publication of PL185320B1 publication Critical patent/PL185320B1/pl

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL95347120A 1994-10-26 1995-10-26 Kompozycja farmaceutyczna do stosowania miejscowego, zawierająca askomycynę PL185320B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421612A GB9421612D0 (en) 1994-10-26 1994-10-26 Organic compounds
PCT/EP1995/004208 WO1996013249A1 (en) 1994-10-26 1995-10-26 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PL185320B1 true PL185320B1 (pl) 2003-04-30

Family

ID=10763457

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95347120A PL185320B1 (pl) 1994-10-26 1995-10-26 Kompozycja farmaceutyczna do stosowania miejscowego, zawierająca askomycynę

Country Status (3)

Country Link
CZ (1) CZ290219B6 (cs)
GB (1) GB9421612D0 (cs)
PL (1) PL185320B1 (cs)

Also Published As

Publication number Publication date
GB9421612D0 (en) 1994-12-14
CZ290219B6 (cs) 2002-06-12

Similar Documents

Publication Publication Date Title
Allen et al. Cerebral arterial spasm: Part 4: In vitro effects of temperature, serotonin analogues, large nonphysiological concentrations of serotonin, and extracellular calcium and magnesium on serotonin-induced contractions of the canine basilar artery
Johansson et al. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299
Yahara et al. Correlation between effects of 24 different cytochalasins on cellular structures and cellular events and those on actin in vitro
DE69431442T2 (de) Topisches wasser
Huerto‐Delgadillo et al. Effects of melatonin on microtubule assembly depend on hormone concentration: role of melatonin as a calmodulin antagonist
CA2309159C (en) Skin penetration enhancing components
DE69125230T2 (de) Tricyclische Verbindungen enthaltende Salben
DE69928542T2 (de) 5HT2-Agonisten zur Behandlung des Glaukoms
CA1106284A (en) Pour-on formulations of anthelmintics
JPH0448774B2 (cs)
McCullough et al. Factors affecting human percutaneous penetration of methotrexate and its analogues in vitro
DE60010596T2 (de) Pyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
WO1997038693A1 (en) Calcium channel blockers as human conjunctival mast cell degranulation inhibitors for treating ocular allergic conditions
KR20000029672A (ko) 크산틴유도체함유지방유제
AU766814B2 (en) Imidazoline receptor binding compounds
PL185320B1 (pl) Kompozycja farmaceutyczna do stosowania miejscowego, zawierająca askomycynę
CA1193546A (en) Process for reducing intraocular pressure
Nowak et al. Effect of repeated treatment with electroconvulsive shock (ECS) on serotonin receptor density and turnover in the rat cerebral cortex
WO1997040033A1 (en) Inhibition of the binding of human ige to its receptor by tetracyclic compounds for the alleviation of ige-mediated immune response
Sharpe et al. Inhibition of cutaneous contact hypersensitivity in the mouse with systemic or topical spiperone: topical application of spiperone produces local immunosuppression without inducing systemic neuroleptic effects
EP0738513A1 (en) Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor
JPH08133979A (ja) 局所適用薬剤組成物
AU767155B2 (en) Small molecule pipecolic acid derivative hair growth compositions and uses
DE10212564A1 (de) 1-Allyl-Ergotalkaloid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Prophylaxe und Therapie von Migräne
Shin et al. Inhibitory effect of anaphylactic shock by caffeine in rats